{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:43Z","timestamp":1790906563794,"version":"4.1.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients\u2019 T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR-T cells to destroy cancerous and other target cells selectively. Despite remarkable clinical improvements in patients, multiple adverse effects have been associated with CAR-T cell therapy. Among the most recognized adverse effects are cytokine release syndrome, immune effector cell\u2013associated neurotoxicity syndrome and tumour lysis syndrome. Even though less recognized, the incidence of acute kidney injury (AKI) ranges from 5 to 33%. The wide range of reported AKI incidence rates might depend on patient population characteristics and comorbidities and specific CAR-T cell therapy features. Even though the exact pathophysiology remains unknown, several key mechanisms, including cytokine release syndrome, tumour lysis syndrome and other factors such as direct renal toxicity of CAR-T cell therapy, conditioning regimens or other medications (e.g. antibiotics), and infectious complications (e.g. sepsis) have been proposed. Risk factors for CAR-T-related AKI include lower baseline glomerular filtration rate, higher rates of allopurinol or rasburicase use, intravenous contrast material exposure, elevated baseline lactate dehydrogenase and grade 3 or higher cytokine release syndrome. Future prospective studies with larger patient populations are needed to gain insights into the pathophysiology of CAR-T-related AKI and, more importantly, to be able to prevent as well as to develop novel and more efficient treatment modalities. In this narrative review, we discuss the underlying pathophysiology, risk factors, potential interventions and future directions related to AKI following CAR-T cell therapy.<\/jats:p>","DOI":"10.1093\/ckj\/sfae359","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T03:15:17Z","timestamp":1731726917000},"source":"Crossref","is-referenced-by-count":16,"title":["Acute kidney injury following CAR-T cell therapy: a nephrologist\u2019s perspective"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berk","family":"Mizrak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi N","family":"Alper","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"2025020409381154200_bib1","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"2025020409381154200_bib2","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"2025020409381154200_bib3","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2025020409381154200_bib4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"2025020409381154200_bib5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025020409381154200_bib6","doi-asserted-by":"publisher","first-page":"2040620719841581","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2025020409381154200_bib7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020409381154200_bib8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2025020409381154200_bib9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s44228-023-00037-7","article-title":"Safety of CAR-T cell therapy in patients with renal failure\/acute kidney injury: focused review","volume":"5","author":"Khan","year":"2023","journal-title":"Clin Hematol Int"},{"key":"2025020409381154200_bib10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bulcan.2022.08.014","article-title":"Acute kidney injury after CAR-T cell infusion","volume":"111","author":"Rousseau","year":"2024","journal-title":"Bull Cancer"},{"key":"2025020409381154200_bib11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025020409381154200_bib12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025020409381154200_bib13","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"2025020409381154200_bib14","doi-asserted-by":"publisher","first-page":"110311","DOI":"10.1016\/j.clim.2024.110311","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy: epidemiology, mechanism and prognosis","volume":"266","author":"Yang","year":"2024","journal-title":"Clin Immunol"},{"key":"2025020409381154200_bib15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.mayocpiqo.2021.01.004","article-title":"Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction","volume":"5","author":"Qin","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2025020409381154200_bib16","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.bcp.2024.116203","article-title":"Butyrate promotes kidney resilience through a coordinated kidney protective response in tubular cells","volume":"224","author":"Favero","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"2025020409381154200_bib17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ndt\/gfz169","article-title":"Loss of NLRP6 expression increases the severity of acute kidney injury","volume":"35","author":"Vali\u00f1o-Rivas","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025020409381154200_bib18","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.biopha.2022.113677","article-title":"Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: a clinical and experimental study","volume":"154","author":"Mora-Fern\u00e1ndez","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025020409381154200_bib19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1681\/ASN.2021030383","article-title":"Bone marrow-derived RIPK3 mediates kidney inflammation in acute kidney injury","volume":"33","author":"Martin-Sanchez","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025020409381154200_bib20","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1073\/pnas.1716578115","article-title":"TWEAK and RIPK1 mediate a second wave of cell death during AKI","volume":"115","author":"Martin-Sanchez","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025020409381154200_bib21","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council perspectives","volume":"74","author":"Ganatra","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025020409381154200_bib22","doi-asserted-by":"publisher","first-page":"H2815","DOI":"10.1152\/ajpheart.2000.279.6.H2815","article-title":"TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx","volume":"279","author":"Henry","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025020409381154200_bib23","doi-asserted-by":"publisher","first-page":"11063","DOI":"10.1111\/jcmm.17029","article-title":"Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia","volume":"25","author":"Hong","year":"2021","journal-title":"J Cell Mol Med"},{"key":"2025020409381154200_bib24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025020409381154200_bib25","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1681\/ASN.2014111090","article-title":"Direct reversible kidney injury in familial hemophagocytic lymphohistiocytosis type 3","volume":"26","author":"Malaga-Dieguez","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"2 Suppl","key":"2025020409381154200_bib26","doi-asserted-by":"publisher","first-page":"S451","DOI":"10.1016\/j.jtct.2023.12.653","article-title":"Incidence of laboratory tumor lysis syndrome in CAR T-cell recipients","volume":"30","author":"Sicre","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025020409381154200_bib27","doi-asserted-by":"publisher","first-page":"1125357","DOI":"10.3389\/fimmu.2023.1125357","article-title":"Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed\/refractory multiple myeloma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2025020409381154200_bib28","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025020409381154200_bib29","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"2025020409381154200_bib30","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025020409381154200_bib31","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.xkme.2021.06.011","article-title":"Collapsing focal segmental glomerulosclerosis and acute kidney injury associated with chimeric antigen receptor T-cell (CAR-T) therapy: a case report","volume":"3","author":"Acharya","year":"2021","journal-title":"Kidney Med"},{"key":"2025020409381154200_bib32","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.1991.9.9.1562","article-title":"A loading dose\/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia","volume":"9","author":"Puccio","year":"1991","journal-title":"J Clin Oncol"},{"key":"2025020409381154200_bib33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"key":"2025020409381154200_bib34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide-and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urology"},{"key":"2025020409381154200_bib35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025020409381154200_bib36","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2025020409381154200_bib37","doi-asserted-by":"publisher","first-page":"sfae123","DOI":"10.1093\/ckj\/sfae123","article-title":"Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes","volume":"17","author":"Vincendeau","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025020409381154200_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.hemonc.2021.09.001","article-title":"Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma","volume":"16","author":"Forero-Forero","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2025020409381154200_bib39","doi-asserted-by":"publisher","first-page":"sfae027","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies","volume":"17","author":"Le\u00f3n-Rom\u00e1n","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025020409381154200_bib40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025020409381154200_bib41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"2025020409381154200_bib42","first-page":"abstract 1493","article-title":"Novel BCMA-CD19 compound CAR-T (cCAR) targets B cells and plasma cells achieving immune reset and eliminates all autoantibodies in systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients resulting in long-term, medication-free remission","volume":"75","author":"Yong Yuan","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025020409381154200_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/annrheumdis-2023-eular.3736","article-title":"OP0141 Long term safety and efficacy of CAR-T cell treatment in refractory systemic lupus erythematosus\u2014data from the first seven patients","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025020409381154200_bib44","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025020409381154200_bib45","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025020409381154200_bib46","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"2025020409381154200_bib47","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.xkme.2021.03.011","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient","volume":"3","author":"Melilli","year":"2021","journal-title":"Kidney Med"},{"key":"2025020409381154200_bib48","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"key":"2025020409381154200_bib49","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.clml.2022.07.007","article-title":"Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients","volume":"22","author":"Ahmed","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2025020409381154200_bib50","doi-asserted-by":"crossref","first-page":"829.e1","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025020409381154200_bib51","doi-asserted-by":"publisher","first-page":"100856","DOI":"10.1016\/j.xkme.2024.100856","article-title":"Chimeric antigen receptor (CAR) T-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: a report of 2 cases","volume":"6","author":"Pak","year":"2024","journal-title":"Kidney Med"},{"key":"2025020409381154200_bib52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"2025020409381154200_bib53","first-page":"151","article-title":"Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse","volume":"51","author":"Huang","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"2025020409381154200_bib54","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute kidney injury after the CAR-T therapy tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025020409381154200_bib55","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00467-024-06331-7","article-title":"Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia","volume":"39","author":"Petgrave","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"2025020409381154200_bib56","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"key":"2025020409381154200_bib57","doi-asserted-by":"publisher","first-page":"664421","DOI":"10.3389\/fonc.2021.664421","article-title":"A prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory B Cell non-Hodgkin lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae359\/60687478\/sfae359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae359\/60687478\/sfae359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae359\/60687478\/sfae359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:38:24Z","timestamp":1738661904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae359\/7901355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae359","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,15]]},"article-number":"sfae359"}}